ReviewNature reviews. Gastroenterology & hepatology2012
Intraductal papillary mucinous neoplasms of the pancreas--a surgical disease.
Review in Nature reviews. Gastroenterology & hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 68 citations in OpenAlex.
- Portuguese Pancreatic Club Perspective on Epidemiology, Classification, and Natural History of Pancreatic Intraductal Papillary Mucinous Neoplasms.GE Portuguese journal of gastroenterology · 2025Review
- Photon-counting CT: technical features and clinical impact on abdominal imaging.Abdominal radiology (New York) · 2024Review
- An Overview for Clinicians on Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas.Cancers · 2024Review
- Utility of Radiological Follow Up of Main-Duct Intraductal Papillary Mucinous Neoplasms and Mixed-Type Intraductal Papillary Mucinous Neoplasms.Biomedicines · 2024Article
- SDC1 and ITGA2 as novel prognostic biomarkers for PDAC related to IPMN.Scientific reports · 2023Article
- New Diagnostic Modality Combining Mass Spectrometry and Machine Learning for the Discrimination of Malignant Intraductal Papillary Mucinous Neoplasms.Annals of surgical oncology · 2023Article
- Carbohydrate antigen 125 supplements carbohydrate antigen 19-9 for the prediction of invasive intraductal papillary mucinous neoplasms of the pancreas.World journal of surgical oncology · 2022Article
- Clinical Implication of Preoperative C-Reactive Protein/Albumin Ratio in Malignant Transformation of Intraductal Papillary Mucinous Neoplasm: A Propensity Score Analysis.Diagnostics (Basel, Switzerland) · 2022Article
- Prognostic Analysis of Different Metastatic Patterns in Invasive Intraductal Papillary Mucinous Neoplasm: A Surveillance, Epidemiology, and End Results Database Analysis.Canadian journal of gastroenterology & hepatology · 2021Article
- Validation and head-to-head comparison of four models for predicting malignancy of intraductal papillary mucinous neoplasm of the pancreas: A study based on endoscopic ultrasound findings.World journal of gastrointestinal oncology · 2019Article
- Surgery of Cystic Tumors of the Pancreas - Why, When, and How?Visceral medicine · 2018Review
- Article
- Familial Pancreatic Cancer and the Future of Directed Screening.Gut and liver · 2017Review
- [Branch duct intraductal papillary mucinous neoplasm - surgical approach].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2017Review
- Evaluating IPMN and pancreatic carcinoma utilizing quantitative histopathology.Cancer medicine · 2016Article
- Analysis of clinical characteristics and treatment of pancreatic cystic tumors.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2016Article
- MIB-1 labeling index, Ki-67, is an indicator of invasive intraductal papillary mucinous neoplasm.Molecular and clinical oncology · 2016Article
- Implications of imaging criteria for the management and treatment of intraductal papillary mucinous neoplasms - benign versus malignant findings.European radiology · 2015Article
- Natural History and Management of Intraductal Papillary Mucinous Neoplasms: Current Evidence.Viszeralmedizin · 2015Review
- International Consensus Guidelines parameters for the prediction of malignancy in intraductal papillary mucinous neoplasm are not properly weighted and are not cumulative.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic pancreatic neoplasms are increasingly recognized, with intraductal papillary mucinous neoplasms of the pancreas (IPMNs) being the most frequently observed type. IPMNs are characterized by mucin production and epithelial growth within the pancreatic ducts, and are generally differentiated according to location: main pancreatic duct, its major side branches, or both (mixed type). IPMNs vary from benign to malignant and are considered precursor lesions of pancreatic adenocarcinoma. However, the exact time to neoplastic transformation and whether all IPMNs progress to malignant tumors is unclear. Surgical resection is warranted for all main-duct and mixed-type IPMNs (they harbor a high risk of malignancy of ~70%). By contrast, branch-duct IPMNs progress to cancer in only ~30% of cases. Thus, according to current guidelines (Sendai criteria), asymptomatic side-branch IPMNs <3 cm in size without suspicious radiological features (such as size progression) can be treated conservatively. Lately, even this approach has become controversial, owing to a number of Sendai-negative IPMNs showing malignant transformation. Although most IPMNs should be resected by standard oncological procedures (including lymphadenectomy), small Sendai-negative IPMNs can be treated with limited resections. This Review summarizes current knowledge of the treatment of IPMNs, with a particular focus on surgical approaches to this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.